09.24.15
PlaqueTec Ltd., a Cambridge-based company developing a biomarker-based approach designed to transform the understanding of coronary artery disease (CAD), the leading cause of death worldwide, appointed Tim Brears as chief executive officer.
Dr. Brears has many years’ experience in the biopharmaceutical industry and was, until recently, chief executive of Xention Limited, a company he founded in 2002 and which has become a leader in the development of drugs for the control of atrial fibrillation. Prior to forming Xention, he was chief executive of Gendaq Limited, a gene-regulation company, which was acquired by Sangamo Biosciences in 2001.
PlaqueTec is capitalizing on the lack of biomarkers available to inform the development of new cardiovascular drugs. Its proprietary technology can be used to assess the performance and potential differentiation of existing drugs, to facilitate the development of new drugs, to better understand mechanisms for the treatment of CAD, to develop patient-specific information and more accurately predict the risk of heart attack and to stratify target populations for specific drug therapies. The company’s approach has been validated in two clinical studies to date.
Dr. Brears has many years’ experience in the biopharmaceutical industry and was, until recently, chief executive of Xention Limited, a company he founded in 2002 and which has become a leader in the development of drugs for the control of atrial fibrillation. Prior to forming Xention, he was chief executive of Gendaq Limited, a gene-regulation company, which was acquired by Sangamo Biosciences in 2001.
PlaqueTec is capitalizing on the lack of biomarkers available to inform the development of new cardiovascular drugs. Its proprietary technology can be used to assess the performance and potential differentiation of existing drugs, to facilitate the development of new drugs, to better understand mechanisms for the treatment of CAD, to develop patient-specific information and more accurately predict the risk of heart attack and to stratify target populations for specific drug therapies. The company’s approach has been validated in two clinical studies to date.